Omarigliptin
As of the edition of 20 October 2026, Omarigliptin is a small molecule: marketed, first approved in 2015 (JP); acts on DPP4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Marizev
- First approved
- 28 September 2015 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 17, 2 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| DPP4 | Dipeptidyl peptidase 4 | P27487 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 11 | 9 | 0 | 2 |
| Phase 4 | 2 | 1 | 0 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant and Lead sponsor of trials | 2010 to now |